Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial (RAPIDO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01558921 |
Recruitment Status :
Active, not recruiting
First Posted : March 20, 2012
Last Update Posted : January 13, 2023
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rectal Cancer | Other: M1 scheme Other: standard long course chemoradiotherapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 920 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | standard arm: 5.5 weeks chemoradiation -> surgery -> optional chemotherapy experimental arm: 5x5Gy -> 12 wks chemotherapy -> surgery |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy. |
Actual Study Start Date : | June 21, 2011 |
Actual Primary Completion Date : | March 8, 2020 |
Estimated Study Completion Date : | December 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: B: 5x5Gy -> CAPOX -> surgery
experimental group (arm B) M1 scheme
|
Other: M1 scheme
short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX |
Active Comparator: A: 5 weeks chemoradiation -> surgery
control group (arm A) standard long course chemoradiotherapy
|
Other: standard long course chemoradiotherapy
long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group. |
- Disease related Treatment Failure (DrTF) [ Time Frame: 3 year follow-up after surgery ]DrTF = Either local or distant relapse or death caused by the rectal carcinoma whichever comes first. In case of nonrectal cancer related death patients will be censored at date of death. In case of a second primary tumour patients will be censored at the date of diagnosis of the second primary tumour. In case of local regrowth after wait & watch strategy, followed by no resection or R2 resection, diagnosis local regrowth is taken. Patients lost to follow-up will be censored the last date of patient visit. Survival curves for Disease related Treatment Failure after 3 years of follow-up will be constructed using the method of Kaplan and Meier.
- Overall survival [ Time Frame: 10 year ]
Overall survival will be computed as the time between randomization and colorectal cancer or treatment related death. Patients lost to follow-up will be censored the last date of patient visit.
In case of a second primary tumour patients will be censored at the date of diagnosis of the second primary tumour.
- CRM negative rate [ Time Frame: within 30 days ]Circumferential resection margin > 1 mm
- pCR rate [ Time Frame: within 30 days ]Pathological complete response after neo-adjuvant treatment
- Short and long-term toxicity [ Time Frame: 3 year follow-up ]Treatment associated toxicity
- Surgical complications [ Time Frame: 3 year follow-up ]Wound rupture, bleeding, infection, rectal anastomotic leak
- Quality of life QLQ-C30 [ Time Frame: 3 year after surgery ]Quality of life QLQ-C30
- Quality of life QLQ-CR-29+ [ Time Frame: 3 year after surgery ]Quality of life QLQ-CR-29+
- Quality of life QLQ-CIPN20 [ Time Frame: 3 year after surgery ]Quality of life QLQ-CIPN20
- Quality of life LARS [ Time Frame: 3 year after surgery ]LARS
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Primary tumour characteristics:
- Histological proof of newly diagnosed primary adenocarcinoma of the rectum
- Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI indicating high risk of failing locally and/or systemically (T4a, i.e. overgrowth to an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum, pelvic floor or side wall (according to TNM version 5), cT4b, i.e. peritoneal involvement, extramural vascular invasion (EMVI+). N2, i.e. four or more lymph nodes in the mesorectum showing morphological signs on MRI indicating metastatic disease. Positive MRF, i.e. tumor or lymph node < 1 mm from the mesorectal fascia. Enlarged lateral nodes, > 1 cm (lat LN+)
Exclusion Criteria:
- Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen
- Presence of metastatic disease or recurrent rectal tumour
- Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn¡¦s disease or active ulcerative Colitis
- Concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years
- Known DPD deficiency
- Any contraindications to MRI (e.g. patients with pacemakers)
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent
- Concurrent uncontrolled medical conditions
- Any investigational treatment for rectal cancer within the past month
- Pregnancy or breast feeding
- Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
- Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months
- Patients with symptoms or history of peripheral neuropathy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01558921
Principal Investigator: | B. van Etten, MD, PhD | University Medical Center Groningen, Department of Surgery, Groningen, The Netherlands | |
Principal Investigator: | B. Glimelius, MD, PhD | Akademiska Sjukhuset, Department of Oncology, Uppsala, Sweden | |
Principal Investigator: | G. A. Hospers, MD, PhD | University Medical Center Groningen, Department of Medical Oncology, Groningen, The Netherlands | |
Principal Investigator: | P. Nilsson, MD, PhD | Karolinska Universitetssjukhuset, Stockholm, Sweden | |
Principal Investigator: | C. J. van de Velde, MD, PhD | Leiden University Medical Center, Department of Surgery, Leiden, The Netherlands | |
Principal Investigator: | C.A.M. Marijnen, MD, PhD | Netherlands Cancer Institute, Amsterdam, the Netherlands |
Documents provided by B. van Etten, MD, PhD, University Medical Center Groningen:
Publications:
Responsible Party: | B. van Etten, MD, PhD, Dr. B. van Etten, surgical oncologist, University Medical Center Groningen |
ClinicalTrials.gov Identifier: | NCT01558921 |
Other Study ID Numbers: |
NL36315.042.11 2010-023957-12 ( EudraCT Number ) |
First Posted: | March 20, 2012 Key Record Dates |
Last Update Posted: | January 13, 2023 |
Last Verified: | January 2023 |
rectal cancer radiotherapy chemotherapy 5x5 capecitbine |
oxaliplatin CAPOX FOLFOX folinic acid fluorouracil |
Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases |